Recombinant Human IL-13 R alpha 2 Fc Chimera (CHO), CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human IL-13 R alpha 2 Fc Chimera (CHO), CF Summary

• Details of Functionality: Measured by its ability to inhibit IL-13-dependent proliferation of TF‑1 human erythroleukemic cells. Kitamura, T. et al. (1989) J. Cell Physiol. 140:323. The ED₅₀ for this effect is 0.1-0.5 μg/mL in the presence of 8 ng/mL recombinant human IL-13.
• Source: Chinese Hamster Ovary cell line, CHO-derived human IL-13 R alpha 2 protein
  

  Human IL-13 R alpha 2 (Cys22-Leu342) Accession # NP_000631	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: NP_000631.1
• N-terminal Sequence: Cys22
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: IL13RA2
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 64 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 75-95 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human IL-13 R alpha 2 Fc Chimera (CHO), CF

• cancer/testis antigen 19
• CD213a2 antigen
• CD213a2
• CT19
• IL-13 R alpha 2
• IL-13 receptor subunit alpha-2
• IL13BP
• IL13R alpha 2
• IL-13R subunit alpha-2
• IL13R
• IL-13R
• IL13RA2
• IL-13Ra2
• IL-13R-alpha-2
• interleukin 13 binding protein
• interleukin 13 receptor alpha 2 chain
• interleukin 13 receptor, alpha 2
• interleukin-13 receptor subunit alpha-2
• Interleukin-13-binding protein

Background

Interleukin‑13 Receptor alpha 2 (IL‑13 R alpha 2), also known as IL‑13 binding protein, and CD213a2, is a widely expressed 55 kDa cytokine receptor that plays an important role in the Th2‑polarized immune responses characteristic of a variety of pathologies, including parasitic infections and allergic asthma (1, 2). Mature human IL‑13 R alpha 2 consists of a 317 amino acid (aa) extracellular domain with three fibronectin type‑III domains, a WSxWS motif, a 20 aa transmembrane segment, and a 17 aa cytoplasmic domain (3). Within the ECD, human IL‑13 R alpha 2 shares 64% and 62% aa sequence identity with mouse and rat IL‑13 R alpha 2, respectively. In both mouse and human, a 40 kDa‑50 kDa soluble form of IL‑13 R alpha 2 can be generated by MMP‑8 mediated shedding in vitro (4).  Although this is assumed to occur in vivo in mouse, there is no evidence that shedding occurs in human (5‑7).  In mouse, alternative splicing also leads to sIL‑13 R alpha 2, but again, this phenomenon apparently does not occur in human (6‑7).  Thus, the biological effects of human IL‑13 R alpha 2 would appear to be mediated exclusively by membrane IL‑13 R alpha 2 (7). The biological effects of IL‑13 and IL‑4 are closely related in part due to a shared receptor system. IL‑13 binds to IL‑13 R alpha 1 which then forms a signaling complex with IL‑4 R alpha (8, 9). IL‑13 R alpha 2 functions as a decoy receptor by binding and internalizing IL‑13 and preventing it from signaling through the IL‑13 R alpha 1/IL‑4 R alpha complex (3, 10). IL‑13 R alpha 2 can also block IL‑4 induced responses by inhibiting IL‑4 bound IL‑13 R alpha 1/IL‑4 R alpha receptor complexes even though it does not itself bind IL‑4 (11, 12). Aside from its decoy function, IL‑13‑activated IL‑13 R alpha 2 directly promotes the development of tissue fibrosis by inducing the transcription of TGF‑ beta (13). Presumably, any human soluble IL‑13 R alpha 2, if it exists, will retain its ligand binding capability and attenuate responses to IL‑13 but not to IL‑4 (11, 14). The up‑regulation of transmembrane during Th2‑biased immune responses limits the extent of those responses (15‑17).

1. Wynn, T.A. (2003) Annu. Rev. Immunol. 21:425.
2. Tabata, Y. et al. (2007) Curr. Allergy Asthma Rep. 7:338.
3. Caput, D. et al. (1996) J. Biol. Chem. 271:16921.
4. Chen, W. et al. (2008) J. Allergy Clin. Immunol. 122:625.
5. O’Toole, M. et al. (2008) Clin. Exp. Allergy 38:594.
6. Chen, W. et al. (2009) J. Immunol. 183:7870.
7. Kasaian, M.T. et al. (2011) J. Immunol. 187:561.
8. Andrews, A.-L. et al. (2006) J. Immunol. 176:7456.
9. Zurawski, S.M. et al. (1995) J. Biol. Chem. 270:13869.
10. Donaldson, D.D. et al. (1998) J. Immunol. 161:2317.
11. Andrews, A.-L. et al. (2006) J. Allergy Clin. Immunol. 118:858.
12. Rahaman, S.O. et al. (2002) Cancer Res. 62:1103.
13. Fichtner-Feigl, S. et al. (2006) Nat. Med. 12:99.
14. Zhang, J.G. et al. (1997) J. Biol. Chem. 272:9474.
15. Chiaramonte, M.G. et al. (2003) J. Exp. Med. 197:687.
16. Morimoto, M. et al. (2009) J. Immunol. 183:1934.
17. Zheng, T. et al. (2008) J. Immunol. 180:522.

Publications for IL-13R alpha 2 (7147-IR)(7)

Publications using 7147-IR

• Bagley, SJ;Logun, M;Fraietta, JA;Wang, X;Desai, AS;Bagley, LJ;Nabavizadeh, A;Jarocha, D;Martins, R;Maloney, E;Lledo, L;Stein, C;Marshall, A;Leskowitz, R;Jadlowsky, JK;Christensen, S;Oner, BS;Plesa, G;Brennan, A;Gonzalez, V;Chen, F;Sun, Y;Gladney, W;Barrett, D;Nasrallah, MP;Hwang, WT;Ming, GL;Song, H;Siegel, DL;June, CH;Hexner, EO;Binder, ZA;O'Rourke, DM; Intrathecal bivalent CAR T cells targeting EGFR and IL13R?2 in recurrent glioblastoma: phase 1 trial interim results Nature medicine 2024-03-13 [PMID: 38480922] (Flow Cytometry, Human)
• Pawlowski, KD;Duffy, JT;Tiwari, A;Zannikou, M;Balyasnikova, IV; Bi-Specific Killer Cell Engager Enhances NK Cell Activity against Interleukin-13 Receptor Alpha-2 Positive Gliomas Cells 2023-06-25 [PMID: 37443750] (ELISA Capture, Human)
• LA Stern, S Gholamin, I Moraga, X Yang, S Saravanaku, JR Cohen, R Starr, B Aguilar, V Salvary, JC Hibbard, A Kalbasi, JK Shepphird, J O'Hearn, KC Garcia, CE Brown Engineered IL13 variants direct specificity of IL13Ralpha2-targeted CAR T cell therapy Proceedings of the National Academy of Sciences of the United States of America, 2022-08-08;119(33):e2112006119. 2022-08-08 [PMID: 35939683] (Cell Culture, Human)
• CE Brown, B Aguilar, R Starr, X Yang, WC Chang, L Weng, B Chang, A Sarkissian, A Brito, JF Sanchez, JR Ostberg, M D'Apuzzo, B Badie, ME Barish, SJ Forman Optimization of IL13R?2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma Mol. Ther., 2017-10-05;26(1):31-44. 2017-10-05 [PMID: 29103912] (Cell Culture, Human)
• Bielamowicz K, Fousek K, Byrd T, Samaha H, Mukherjee M, Aware N, Wu M, Orange J, Sumazin P, Man T, Joseph S, Hegde M, Ahmed N Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. Neuro Oncol, 2018-03-27;20(4):506-518. 2018-03-27 [PMID: 29016929] (CAR-T (Bioassay), Human)
• Mahadev V, Starr R, Wright S, Martinez C, Jensen M, Barish M, Forman S, Brown C Cytokine induction of VCAM-1 but not IL13Ralpha2 on glioma cells: a tale of two antibodies. PLoS ONE, 2014-05-02;9(5):e95123. 2014-05-02 [PMID: 24787244] (Bioassay, Human)
• Hegde M, Corder A, Chow K, Mukherjee M, Ashoori A, Kew Y, Zhang Y, Baskin D, Merchant F, Brawley V, Byrd T, Krebs S, Wu M, Liu H, Heslop H, Gottschalk S, Yvon E, Ahmed N Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther, 2013-08-13;21(11):2087-101. 2013-08-13 [PMID: 23939024] (CAR-T (Bioassay), Human)

Bioinformatics

• Gene Symbol: IL13RA2
• Uniprot:
  • NP_000631.1(Human)